Zydus Lifesciences Management

Management Kriterienprüfungen 2/4

Zydus Lifesciences' CEO ist Sharvil Patel, ernannt in Apr 2017, hat eine Amtszeit von 7.08 Jahren. Die jährliche Gesamtvergütung beträgt ₹262.50M, bestehend aus 68.6% Gehalt und 31.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.001% der Aktien des Unternehmens, im Wert von ₹15.92M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6 Jahre bzw. 9 Jahre.

Wichtige Informationen

Sharvil Patel

Geschäftsführender

₹262.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	68.6%
Amtszeit als Geschäftsführer	7.2yrs
Eigentum des Geschäftsführers	0.001%
Durchschnittliche Amtszeit des Managements	6.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.1yrs

Jüngste Management Updates

Recent updates

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Aug 09

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 25

Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50

Jul 10

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sharvil Patel im Vergleich zu den Einnahmen von Zydus Lifesciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	₹38b
Dec 31 2023	n/a	n/a	₹30b
Sep 30 2023	n/a	n/a	₹28b
Jun 30 2023	n/a	n/a	₹25b
Mar 31 2023	₹263m	₹180m	₹20b
Dec 31 2022	n/a	n/a	₹21b
Sep 30 2022	n/a	n/a	₹20b
Jun 30 2022	n/a	n/a	₹22b
Mar 31 2022	₹200m	₹180m	₹22b
Dec 31 2021	n/a	n/a	₹23b
Sep 30 2021	n/a	n/a	₹23b
Jun 30 2021	n/a	n/a	₹23b
Mar 31 2021	₹263m	₹180m	₹22b
Dec 31 2020	n/a	n/a	₹18b
Sep 30 2020	n/a	n/a	₹17b
Jun 30 2020	n/a	n/a	₹13b
Mar 31 2020	₹250m	₹247m	₹12b
Dec 31 2019	n/a	n/a	₹12b
Sep 30 2019	n/a	n/a	₹14b
Jun 30 2019	n/a	n/a	₹17b
Mar 31 2019	₹250m	₹248m	₹18b
Dec 31 2018	n/a	n/a	₹20b
Sep 30 2018	n/a	n/a	₹20b
Jun 30 2018	n/a	n/a	₹21b
Mar 31 2018	₹250m	₹248m	₹18b

Vergütung im Vergleich zum Markt: SharvilDie Gesamtvergütung ($USD3.15M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD974.46K).

Entschädigung vs. Einkommen: SharvilDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.

Geschäftsführer

Sharvil Patel (45 yo)

7.2yrs

Amtszeit

₹262,500,000

Vergütung

Dr. Sharvil Pankajbhai Patel has been Managing Director of Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) since April 1, 2017 and previously served as its Joint Managing Director...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sharvil Patel	MD & Executive Director	7.2yrs	₹262.50m	0.0015% ₹ 16.0m
Ganesh Nayak	COO & Executive Director	6.9yrs	₹120.00m	0.035% ₹ 377.8m
Punit Patel	President & CEO of America	less than a year	keine Daten	keine Daten
Nitinkumar Parekh	Chief Financial Officer	no data	₹54.31m	keine Daten
Arvind Bothra	Head of Investor Relations	no data	keine Daten	keine Daten
Dhaval Soni	Company Secretary & Compliance Officer	5.3yrs	₹2.09m	keine Daten

6.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: Das Managementteam von ZYDUSLIFE ist erfahren und erfahren (durchschnittliche Amtszeit: 6 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sharvil Patel	MD & Executive Director	26.8yrs	₹262.50m	0.0015% ₹ 16.0m
Ganesh Nayak	COO & Executive Director	6.9yrs	₹120.00m	0.035% ₹ 377.8m
Pankaj Patel	Non-Executive Chairman	29.1yrs	₹1.60m	74.98% ₹ 818.6b
Apurva Diwanji	Independent Director	8.1yrs	₹4.60m	keine Daten
Mukeshbhai Patel	Non-Executive Non-Independent Director	26.8yrs	₹4.80m	0.0012% ₹ 12.7m
Bhadresh Shah	Independent Director	5.5yrs	₹4.60m	keine Daten
Dharmishtaben Raval	Non-Executive Independent Director	10.1yrs	₹4.50m	keine Daten
Nitin Desai	Non-Executive Independent Director	13.1yrs	₹4.30m	0.046% ₹ 505.8m
Akhil Monappa	Independent Director	1.6yrs	₹1.20m	keine Daten
Upasana Konidela	Independent Director	1.6yrs	₹1.20m	keine Daten

9.1yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: ZYDUSLIFEDie Vorstandsmitglieder gelten als erfahren (9 Jahre durchschnittliche Amtszeit).

Zydus Lifesciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Insider recently sold ₹833k worth of stock

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Recent updates

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) completed the acquisition of Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma.

Zydus Lifesciences Limited Announces Resignation of Rashmin Shah as President-Special Projects

Upcoming dividend of ₹6.00 per share at 1.0% yield

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Zydus Lifesciences Limited to Report Q3, 2024 Results on Feb 14, 2024

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Zydus Lifesciences Limited Receives Final Approval from the Usfda for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 Mg and 40 Mg

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Price target increased by 7.6% to ₹536

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Zydus Lifesciences Limited, Annual General Meeting, Aug 11, 2023

Zydus Group Reportedly Looks to Sell Cliantha Research

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Sirolimus Tablets, 1 Mg and 2 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Febuxostat Tablets

Zydus Lifesciences Limited Receives Two Final Approvals from the USFDA for Silodosin Capsules and Pregabalin Capsules

Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration to Market Topiramate Extended-Release Capsules

Zydus Lifesciences Limited (NSEI:ZYDUSLIFE) entered into a Business Transfer Agreement to acquire Active pharmaceutical ingredients arm of Watson Pharma from Watson Pharma for approximately INR 470 million.

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Famotidine Injection

Zydus Lifesciences Limited Gets Exclusive Marketing Rights for CanAssist Breast

Insufficient new directors

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets